United States Patent 10,617,651: Scope, Claim Construction, and US Patent Landscape for Oral Methylphenidate Coated Particles With pH-Dependent Lag Time
United States Patent No. 10,617,651 covers an oral methylphenidate sustained-release bead/granule-type formulation with (i) a sustained-release coating layer containing specific hydrophobic/hydrophilic polymer and plasticizer/binder components and (ii) a pH-dependent polymer/copolymer that is insoluble below pH 5.5, producing a defined lag-time release profile in sequential simulated gastric and intestinal media. Independent claim 1 is drafted to a method of treating a methylphenidate-responsive disorder using the claimed coated-particle composition, with multiple dependent claims narrowing to salt form, coating excipient identities, specific pH-dependent polymer, and dosage strength ranges.
What does US Patent 10,617,651 claim in plain terms?
Featured answer (Claim 1):
A method of treating a methylphenidate-responsive condition by orally administering methylphenidate (or a salt) in a coated particle composition that has:
- Core: methylphenidate (or salt)
- Sustained release layer enclosing the core: includes
- water-insoluble and water-permeable polymer
- water-soluble polymer
- hydrophobic plasticizer
- hydrophobic binder
- pH-dependent polymer/copolymer layer or component:
- insoluble in aqueous medium at pH < 5.5
- Release profile requirement (USP Apparatus I):
- In 700 mL of 0.1N HCl, pH 1.1: for up to 2 hours, then
- 4 hours in phosphate buffer pH 6.0, then
- 14 hours in phosphate buffer pH 7.2 at 37°C ±0.5°C,
- The formulation provides at least an 8-hour lag time during which it releases no more than 10% of total methylphenidate, followed by a 10–12 hour sustained release period.
Practical construction: claim 1 is not just about excipient identities; it is about a specific architecture (core + sustained release layer + pH-dependent component) and measurable dissolution behavior under a defined multi-stage test.
How do the independent and dependent claims scope differ in US 10,617,651?
Claim 1 (independent): core + sustained release layer + pH-dependent insolubility + dissolution performance
Claim 1 is the broadest and is supported by:
- product structure (coated particles)
- functional solubility limitation (insoluble below pH 5.5)
- performance limitation (8-hour lag with ≤10% release, then 10–12 hours sustained release)
Claim 2: hydrochloride salt limitation
- Narrows “methylphenidate or salt” to methylphenidate hydrochloride.
Claims 3–4: sustained release layer excipient package (ethyl cellulose + hydroxypropyl cellulose + dibutyl sebacate + metal stearate)
- Claim 3 is method claim: sustained release layer includes
ethyl cellulose, hydroxypropyl cellulose, dibutyl sebacate, and a metal stearate.
- Claim 4 mirrors composition claim and narrows “metal stearate” to magnesium stearate explicitly.
Claim 5: specific pH-dependent polymer
- Narrows pH-dependent copolymer to methacrylic acid copolymer Type B.
Claim 6: additional excipient set
- Adds mono- and diglycerides, dibutyl sebacate, polysorbate 80 (and repeats dibutyl sebacate in the claim text).
Claims 7–8: dosage strength ranges
- Single dosage form containing:
- 1 mg to 150 mg (claim 7)
- 1 mg to 80 mg (claim 8)
These limits constrain marketed dose presentations but do not narrow excipient architecture.
Claim 9: quantitative excipient ratio for sustained release layer
- Sustained release layer comprises:
- ethyl cellulose and hydroxypropyl cellulose in a ratio ~1:3 to 1:5
- dibutyl sebacate
- 25% to 50% by weight magnesium stearate
Net effect: claim 1 captures a formulation category with performance and solubility constraints; dependent claims close gaps with specific excipient identities, polymer type, and measurable formulation composition ratios.
What elements of Claim 1 are the likely infringement “pressure points”?
1) “pH-dependent polymer or copolymer … insoluble in aqueous medium at pH lower than 5.5”
This is a solubility-based functional limitation that will be central in claim construction and expert testimony:
- infringing products need a component that remains insoluble in acidic conditions (<5.5).
- it is not limited to a named polymer in claim 1, though claim 5 identifies one specific option.
2) “at least an 8 hour lag time” defined by USP Apparatus I test sequence
The release profile ties infringement to:
- the test geometry (USP Apparatus I),
- the 700 mL media volume and pH schedule, and
- quantitative thresholds:
- no more than 10% release during the lag phase totaling at least 8 hours
- 10–12 hour sustained release period after the lag.
This kind of limitation tends to drive:
- dissolution testing in litigation,
- construction of “lag time” under the claim and the specified test.
3) Sustained release layer formulation composition (materials class and roles)
Claim 1 requires the sustained release layer to include four classes:
- water-insoluble and water-permeable polymer
- water-soluble polymer
- hydrophobic plasticizer
- hydrophobic binder
That classification creates a route for non-literal disputes:
- whether a given polymer is “water-insoluble and water-permeable”
- whether a plasticizer/binder meets “hydrophobic” and “binder” characterization.
Claims 3–4, 9 convert these class concepts into concrete excipient packages for narrower infringement.
What do claims 3, 4, 9 cover about the sustained release layer composition?
Sustained release layer excipient identities (claims 3–4)
- Ethyl cellulose
- Hydroxypropyl cellulose
- Dibutyl sebacate
- Metal stearate (with magnesium stearate in claim 4)
Sustained release layer composition ratios (claim 9)
- Ethyl cellulose : hydroxypropyl cellulose ratio about 1:3 to 1:5
- Magnesium stearate 25%–50% by weight
- Dibutyl sebacate present
Design-around implications (practical, not speculative):
- A generic that uses different controlled-release polymers or omits or substitutes the specified plasticizer/binder system would be pulled outside claims 3/4/9, though claim 1 could still be asserted if the substitute performs the same functional requirements with equivalent component roles.
How does Claim 5 narrow the pH-dependent component?
Claim 5 specifically identifies methacrylic acid copolymer Type B as the pH-dependent copolymer component.
For infringement analysis:
- products using a different pH-dependent polymer could still fall under claim 1 if the copolymer is insoluble below pH 5.5 and is part of the required particle architecture.
- products using methacrylic acid copolymer Type B would more directly map to claim 5.
What is the dissolution test matrix embedded in Claim 1?
Claim 1 hard-codes the sequential medium conditions, which likely match an intended performance profile:
- Up to 2 hours: 700 mL 0.1 N HCl, pH 1.1
- Next 4 hours: sodium phosphate buffer pH 6.0
- Next 14 hours: sodium phosphate buffer pH 7.2 at 37°C ±0.5°C
- Release outcomes:
- at least 8-hour lag time, with ≤10% of total methylphenidate released during lag
- after lag, 10–12 hour sustained release period
Analytical use: In disputes, the same USP apparatus and media conditions are used to reproduce the claimed release behavior, and parties tend to anchor experts on:
- cumulative release curve
- the time at which cumulative release exceeds 10%
- the duration until release plateaus or ends the sustained window as framed by the claim language
What does “method of treating a subject responsive to methylphenidate” add to claim scope?
Claim 1 is a medical method claim rather than a pure composition claim:
- it covers administration to a subject with a disorder or condition responsive to methylphenidate
- the claim does not limit which disorder (within “responsive”); this is likely intended to cover broad clinical indications where methylphenidate is used (attention-deficit disorders and related conditions).
In practice, this structure can shift infringement analysis to:
- whether the accused product is administered for methylphenidate-responsive conditions, and
- whether the accused product’s formulation matches the claimed coated particle architecture and release profile.
What US patent landscape surrounds US 10,617,651 for methylphenidate oral sustained release?
The patent landscape for extended-release methylphenidate commonly clusters around:
- multi-phase coatings designed to control gastric residence effects and delay release
- matrix vs coated bead systems
- pH-dependent polymers (enteric-like behavior)
- specific excipient packages (cellulose derivatives, plasticizers, stearates)
- release kinetics tuned for once-daily or extended daytime exposure
Given only the provided claim text, the landscape below is constrained to what can be derived from claim scope itself: 10,617,651 sits in the subset of patents asserting that the combination of a pH-insoluble component below pH 5.5 plus a controlled sustained release polymer blend yields a long lag then sustained release under a USP Apparatus I schedule.
Landscape risk area for competitors: patents that also claim:
- coated particles (cores) with an insoluble-on-early-pH component
- cellulose-based sustained release layers with hydrophobic plasticizers and stearate binders
- dissolution profiles specifying lag time and subsequent controlled release duration
Landscape risk area for licensing: parties owning compositions with different but functionally similar release profiles often face cross-licensing or settlement structures to manage lag-time and pH-dependent dissolution performance claims.
Which claim elements would likely drive patentability/validity attacks?
For a US method claim anchored on formulation and dissolution behavior, common attack vectors typically include:
-
Anticipation by prior art dissolution profiles that already taught:
- coated methylphenidate particles,
- pH-dependent insolubility below a threshold around 5.5,
- and delayed release with specified lag windows.
-
Obviousness combining:
- known pH-dependent polymers (e.g., methacrylate copolymers used to control drug release by pH),
- known sustained-release coating systems (ethyl cellulose, hydroxypropyl cellulose, plasticizers, stearates),
- and routine performance tuning.
-
Indefiniteness / clarity challenges around:
- the functional limitation “insoluble at pH lower than 5.5”
- the claim-defined “lag time” as measured by cumulative release behavior and the specific test schedule.
-
Written description and enablement if the specification does not support:
- the full breadth of polymers encompassed by claim 1
- the broad methylphenidate/salt coverage with the same lag-time performance.
(These are litigation and prosecution themes; they are driven directly by the claim’s functional and performance constraints.)
How strong is the patent estate likely to be for 10,617,651 on claim scope?
Within the claim set provided, the strength profile is as follows:
- Broadest coverage: claim 1 is broad as to methylphenidate salt identity and the specific pH-dependent polymer/copolymer (only insolvency at pH < 5.5 is required).
- Narrowest coverage: claims 3–4, 5, 9 pin down specific excipient identities and ratios.
- Infringement leverage: the dissolution test limitations can narrow the effective scope by requiring the same release curve outcome under the exact test schedule.
- Design-around leverage: competitors can attempt to avoid one or more of:
- the pH threshold behavior,
- the 8-hour lag with ≤10% release,
- the sustained release layer composition classes or specific cellulose/plasticizer/binder system.
The result is a patent that can be asserted at two levels:
- broad functional level (claim 1) against products with the same architecture and performance
- narrow excipient and ratio level (claims 3–5, 9) against close formulations.
What generic entry risks exist if a competitor tries to copy the performance profile?
If a competitor targets the same pharmacotechnical outcome (long lag plus extended sustained release), the main risks are:
- Literal capture risk if the competitor uses the same pH-dependent insoluble polymer class and achieves the same release kinetics under USP Apparatus I.
- Near-literal risk if the sustained release layer uses the same or functionally equivalent blend of ethyl cellulose/hydroxypropyl cellulose plus dibutyl sebacate and magnesium stearate, especially in the ratio and percentage bands in claim 9.
Even if a competitor swaps a polymer, claim 1 still requires:
- the sustained-release layer includes the four functional component roles,
- the pH-dependent component is insoluble below pH 5.5,
- and the lag/sustained release time windows are met.
Key Takeaways
- US 10,617,651 Claim 1 is a method-of-use claim tied to a specific coated-particle methylphenidate formulation architecture and a hard dissolution performance requirement: ≥8-hour lag with ≤10% release, then 10–12 hours sustained release under a defined USP Apparatus I multi-stage media sequence.
- The claim set is built for both broad functional coverage (claim 1) and narrow formulation capture (claims 3–5, 9).
- The most litigable claim elements are the pH<5.5 insolubility limitation and the 8-hour lag dissolution endpoint measured under the stated conditions.
- Competitors trying to design around should focus on changing either:
- the pH-dependent insolubility mechanism, or
- the dissolution curve that produces the claimed lag and sustained windows, or
- the sustained-release layer excipient system in a way that removes compliance with the required material roles and, where asserted, the specific excipient package and ratios.
FAQs
1) Does US 10,617,651 require methacrylic acid copolymer Type B to infringe?
No. Type B is explicitly recited in dependent claim 5, but independent claim 1 requires only a pH-dependent polymer/copolymer that is insoluble in aqueous medium at pH lower than 5.5.
2) Can infringement occur with a methylphenidate salt other than hydrochloride?
Yes for claim 1, which covers methylphenidate or pharmaceutical salts. Claim 2 specifically limits to methylphenidate hydrochloride.
3) What part of the claim is most sensitive to dissolution testing methodology?
The “lag time” and “sustained release period” requirements are tied to USP Apparatus I and the specific media schedule and thresholds (≤10% released during the lag, then 10–12 hour sustained release).
4) Do claims 7 and 8 limit infringement to specific dosage strengths only?
They limit those dependent claims to certain strength ranges in a single dosage form, but claim 1 is not limited to those ranges based on the provided text.
5) What is the technical purpose of the pH-dependent insolubility at pH<5.5?
In the claim framework, it is intended to prevent early release in acidic conditions (below pH 5.5), supporting a long lag window before sustained release begins.
References
- United States Patent No. 10,617,651 (claim text provided in prompt).
